Introduction
Fluoroquinolones are a group of antimicrobial agents with a broad and potent activity spectrum which act by inhibiting the activity of type II topoisomerases (DNA gyrase and topoisomerase IV). [1] [2] [3] Development of quinolone resistance can be due to amino acid substitutions in either or both of the two different subunits of the type II topoisomerases. These are both tetrameric enzymes composed of two subunits A and two subunits B, which in the case of DNA gyrase are encoded by the gyrA and gyrB genes, respectively. Quinolone resistance development owing to mutations in the gyrA gene has been well established. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In Escherichia coli, mutations are clustered in the quinolone resistance-determining region (QRDR) located between amino acids Ala-67 and Gln-106, the most frequent being at amino acid codon 83 15 or at equivalent positions in other microorganisms including Citrobacter freundii. 7, 8, 13, 14, 16, 18 The double mutation at amino acid codons Ser-83 and Asp-87 has been related to a high level of quinolone resistance in E. coli. 6, 9, 17 Recently, the presence of mutations out of the QRDR (at amino acid 119 Ala Glu) has been reported in quinolone-resistant Salmonella typhimurium. 8 The mutation of amino acid codon Ala-119 to Ser has also been described in Acinetobacter baumannii, 16 although no relationship has been established between this mutation and the presence of quinolone resistance, since it is present in both quinoloneresistant and quinolone-susceptible strains.
Mutations of amino acid codons 426 and 447 of the gyrB gene of E. coli are also responsible for the acquisition of quinolone resistance, 10, 19, 20 although their relative importance differs in clinical and in-vitro E. coli quinoloneresistant strains. While quinolone-resistant strains show a similar in-vitro frequency of mutations in gyrA and gyrB genes, 10 
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There is a considerable sequence similarity between the genes that encode the A and B subunits of the DNA gyrase and those that encode them for the topoisomerase IV. Recently, it has been shown that topoisomerase IV is a quinolone target in E. coli 3, 21 and that changes at residues Ser-80 and Glu-84 of ParC (A subunit) may contribute to decreasing fluoroquinolone susceptibility. 6, [22] [23] [24] Conversely, the role of ParE, (B subunit of topoisomerase IV) in the acquisition of quinolone resistance in clinical isolates of E. coli seems to be irrelevant, 6 ,25 although mutations in in-vitro quinolone-resistant strains of E. coli have been described by Breines et al. 26 in an analogous position to gyrB gene mutations responsible for quinolone resistance development.
Changes in quinolone accumulation by increased efflux or decreased uptake have also been linked to quinolone resistance acquisition. While the former is usually linked to some kind of pump which actively expels the drug, the latter has been associated with changes in the outer membrane proteins.
Alterations in the gyrA gene of a quinolone-resistant strain of C. freundii were shown for the first time indirectly with an experiment in which the supercoiling activity of the mutant's DNA gyrase was resistant to quinolone compounds. 5 In 1988, Aoyama et al. 27 studied norfloxacin uptake and membrane profiles in a clinically resistant strain and recently, mutations in gyrA and parC have been described in quinolone-resistant clinical strains. 11 However, a comprehensive study of all possible resistance mechanisms in clinical isolates of C. freundii has not yet been reported.
In this work, we have determined the mechanisms of quinolone resistance in clinical isolates of C. freundii by means of sequencing the QRDR of the gyrA, gyrB and parC genes and determining quinolone uptake and outer membrane protein profiles.
Materials and methods

Bacterial isolates
A total of 12 clinical isolates of C. freundii were recovered from different biological samples, from either in-patients or out-patients, submitted to the Clinical Microbiology Laboratory at the Hospital Clinic of Barcelona, Spain.
Antimicrobial susceptibility testing
Susceptibility testing was performed by an agar dilution method in accordance with the guidelines established by the National Committee for Clinical Laboratory Standards. 28 Approximately 10 4 cfu/spot of each isolate was inoculated with a multipoint replicator on to freshly prepared medium containing serial dilutions of ciprofloxacin (Bayer, Leverkusen, Germany), nalidixic acid (Prodesfarma, Barcelona, Spain) or chloramphenicol (Sigma, St Louis, MO, USA)
REP (repetitive extragenic palindromic) PCR
REP-PCR was carried out using the primer 5 GCG CCG ICA TGC GGC ATT 3 under the following conditions: 30 cycles of 1 min at 94 C, 1 min at 40 C, 1 min at 65 C and a final extension at 65 C for 16 min. The reaction was prepared using 5 L of boiled bacterial suspension, 1 L of 5 M primer and a PCR bead (Pharmacia Biotech, Uppsala, Sweden) in a final volume of 25 L. Five microlitres of the amplification product was separated in a 12.5% precast polyacrylamide gel using a GenePhor apparatus (Pharmacia Biotech) and silver-stained using the Pharmacia Biotech DNA silver staining kit.
Ciprofloxacin uptake
Ciprofloxacin uptake was determined as previously described by Asuquo & Piddock. 29 
Amplification and DNA sequencing of quinolone resistance determining region (QRDR) in gyrA and parC genes
The PCR amplification of the QRDR gyrA gene was carried out using the primers and following the conditions previously described by Vila et al. 16 The parC QRDR was amplified using the sense primer described for E. coli 23 and an antisense consensus primer designed by comparing several published parC gene sequences. The sequence of the antisense primer was 5 -CAT CGC CGC GAA CGA TTC GG-3 . The PCR conditions were the same as for gyrA amplification. 16 To amplify the gyrB fragment, primers and conditions used were as described previously. 16 The PCR reactions were performed using a DNA thermal cycler 480 (Perkin-Elmer Cetus, Emeryville, CA, USA). Amplified DNA products were resolved by electrophoresis in agarose gels (2%, w/v) containing 0.5 mg/L of ethidium bromide. PCR products were recovered directly from the agarose gel and purified. DNA sequencing was performed with the TaqDyeDeoxyTerminator Cycle Sequencing kit (Applied Biosystems) and analysed in an automatic DNA sequencer (Applied Biosystems 377).
The EMBL accession numbers for the partial sequences are: gyrA, AF064797; parC, AF064798 and gyrB, AF071877.
Outer membrane protein profile analysis
Outer membrane proteins were prepared with N-lauroylsarcosine as previously described. 30 Proteins were separated by electrophoresis using 10% urea-SDS-polyacrylamide gel and silver stained using the PharmaciaBiotech protein silver staining kit. (Figure 1 ). All the susceptible isolates and most of the nalidixic acid-resistant/ciprofloxacinsusceptible ones were different strains, with the exception of 16.0, 16.4 and 16.5 which showed the same pattern. The resistant strains can be grouped as pairs: isolates 1.2 and 1.25 were the same clone, as were isolates 1.44 and 1.38. These latter isolates came from the same patient.
Results
REP-PCR of the 12 C. freundii isolates showed eight different patterns
The PCR products obtained with the aforementioned primers for gyrA, gyrB and parC had the expected sizes, that is 343 bp, 447 bp and 240 bp, respectively. In the case of gyrA and parC, a fragment of the genes had been previously amplified. 11 Our fragments had 100% homology with those described, although in both cases we sequenced a larger amplified fragment. As for gyrB, nucleotide identity with E. coli was 90.58% and between 90.42% and 54.38% with equivalent regions of other microorganisms while amino acid alignment showed 97.1% with E. coli and between 44.9% and 93.75% with the remainder (Figure 2) .
The four quinolone-susceptible strains (nalidixic acid MIC 2-4 mg/L and ciprofloxacin MIC 0.006-0.06 mg/L) all had the wild-type amino acid threonine at position 83 of GyrA (Table I ). The remaining eight strains were classified The outer membrane protein profiles for the four isolates belonging to group D including the four resistant strains (group B), two susceptible strains (8 and 14) and two strains from group A (14.1 and 16.4) were investigated. No major differences were observed in the expression of OmpF, OmpC and OmpA (Figure 3 only shows the results for the four resistant strains). However, differences were observed in the amount of ciprofloxacin accumulated by the different strains tested (Table II) . Strain 1.38 showed less accumulation than its pair strain 1.44 and the addition of carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) produced an increase in the uptake of 51% for strain 1.38 and only of 8.7% for strain 1.44. The MIC of chloramphenicol for strain 1.38 was 128 mg/L and for strain 1.44 was 12 mg/L.
Discussion
The presence of gyrA, gyrB and parC mutations, differences in the ciprofloxacin uptake and OMP profiles of 12 clinical isolates of C. freundii have been analysed. In agreement with previously published results, all the nalidixic acid-resistant clinical isolates included in this study showed a mutation resulting in an amino acid substitution at the Thr-83 position (equivalent to Ser-83 of E. coli). Besides, three of them (ciprofloxacin MIC 8-32 mg/L) also showed a second substitution at the position equivalent to amino acid 87 of E. coli ( A s p Tyr). The four isolates that showed resistance to both quinolones employed, also had a mutation in the p a r C gene at the position equivalent to the residue Ser-80 of E. coli ( S e r Ile). We did not find the mutation at Glu-84 (Glu Lys) described by Nishino et al. 1 1 N o mutations were found in the analysed region of g y r B o f any of the strains studied. These results suggest that in C. freundii, as in E. coli, the primary quinolone acquisition point is located in GyrA. Besides, a single substitution at position 83 of the GyrA is sufficient for developing a very high nalidixic acid resistance level (MIC 1024 mg/L), yet retaining susceptibility to ciprofloxacin (0.25-0.5 mg/L). This is clearly seen with isolates 16.0 and 16.4 or 16.5, which belong to the same REP-PCR type. The same has been described in E. coli 1 5 , 1 7 where a change in Ser-83 was Even though the topoisomerase-mediated resistance (specifically mutations in gyrA and parC genes) can explain in general terms the MICs of the strains under study, differences within group B (resistant to both quinolones tested) need further explanation. C. freundii outer membrane proteins have been described previously. 27 As in E. coli there are three major proteins, although their electrophoretic mobilities are different. A decrease in the expression of an outer membrane porin has been associated with a decrease in quinolone uptake. 27 In our study, no major differences were observed in the expression of the isolates' OmpC, OmpF and OmpA profiles.
Differences did appear, however, in the amount of ciprofloxacin accumulated. Strains 1.44 and 1.38 belong to the same REP-PCR type, have the same gyrase and topoisomerase mutations but differ in their ciprofloxacin MIC. Such a difference could be attributed to strain 1.38 having a more important active efflux than 1.44, which is suggested by the former's increased ciprofloxacin uptake in the presence of CCCP. This suggestion is supported by the fact that the chloramphenicol MIC for strain 1.38 was higher than that for strain 1.44. This is probably due to the fact that the active efflux system pumping ciprofloxacin out of the cell also takes chloramphenicol.
In summary, in C. freundii, as in E. coli, high levels of quinolone resistance are due to mutations in g y r A and p a r C genes, with the former having the primary priority point mutation. In addition, an overexpressed active efflux pump responsible for increasing already high levels of resistance to ciprofloxacin was also observed in resistant strains. 
